Following the cloning of the cystic fibrosis (CF) gene, in vitro studies rapidly established the feasibility of gene therapy for this disease. Unlike ex vivo approaches that have been utilized for other genetic diseases such as adenosine deaminase deficiency, gene therapy for CF will likely require direct in vivo delivery of gene transfer vectors to the airways of patients with CF. Hence, major research efforts have been directed at the development of efficient gene transfer vectors that are safe for use in human subjects. Several vectors have now emerged from the laboratory for evaluation in clinical safety and efficacy trials in the United States and in the United Kingdom. Adenovirus-mediated gene transfer has been utilized for initial clinical safety and efficacy trials in the United States, while liposome-mediated gene transfer has been chosen for initial clinical safety and efficacy trials in the United Kingdom. The rationale and r ystic fibrosis (CF) is an autosomal recessive disorder affecting 1 in 2,500 live white births.' The disease is characterized by abnormal salt and water transport that leads to abnormal airway secretions, impaired mucociliary clearance, chronic bacterial infection, bronchiectasis, and premature death.'12 A variety of epithelial tissues are affected in this disease, including airway, pancreatic, sweat ductal, and gastrointestinal epithelia. '12 However, lung disease is the major cause of morbidity and mortality in this disorder. Accordingly, initial gene therapy efforts have been directed toward lung disease.
The CF gene, which codes for the CF transmembrane conductance regulator (CFTR) protein, was cloned in 1989,3 and since that time, more than 300 mutations have been reported. The most common mutation is a three base pair deletion leading to deletion of phenylalanine (F) at position 508 (AF508) of the gene. This mutation leads to abnormal intracellular processing and trafficking of the mutant CFTR, and ultimately to defective apical membrane chloride (Cl-) conductance in epithelial cells affected by this disorder.5 Several investigators have proved that the protein product of CFTR is a cyclic adenosine monophosphate (cAMP)-mediated Cl-channel. [6] [7] [8] Because CF is an autosomal recessive disorder, introduction of a normal copy of the gene into the host cell should result in restoration of normal Cl-transport function. In studies published by Drumm Table  1 , and they are described in more detail below.
Retrovirus Vectors
Retrovirus-mediated gene transfer is the method of gene transfer utilized in most currently approved human gene transfer trials.'3 While human immunodeficiency virus is the most commonly known retrovirus, most retroviruses are structurally similar. They are all RNA viruses that have two viral long terminal repeats that are important for cellular integration and also contain promoter elements, a packaging signal, and a series of structural genes, gag, pol, and env. The gag gene encodes a precursor polypeptide that is cleaved to yield the capsid protein.
The pol gene encodes reverse transcriptase and an enzyme involved in proviral integration. The env gene encodes the precursor to the envelope glycoprotein. A retrovirus vector is constructed by deleting the gag, pol, and env genes using restriction enzymes and inserting or cloning desired cDNAs (genes) into the remaining retrovirus genome.'4 Exogenous promoters may also be included in the sequences of the inserted gene or alternatively, the viral 5' long terminal repeat may be used to drive transcription of the inserted gene. Because these retrovirus vectors have had their viral genes deleted, they are replication-defective.
When a wild-type retrovirus infects a cell, glycoproteins on the virus particle bind to a specific cell surface receptor, which results in fusion and emptying of the nucleocapsid containing the RNA and its reverse transcriptase into the cytoplasm of the host cell. The RNA is reverse transcribed to form a cDNA, the provirus, which is translocated to the nucleus, where it integrates into the host cell chromosomes. The integrated provirus, through the normal process of DNA transcription, encodes new viral proteins and new viral RNA, which are assembled at the cell surface into new virus particles. When a replicationdefective retrovirus vector infects a cell, its RNA is also reverse transcribed to form the provirus, which integrates into the host cell genome. However, unlike wild-type viruses, the integrated provirus from a retrovirus vector does not produce viral proteins or viral RNA. Instead, it encodes the inserted gene.
Because the retrovirus vector genome integrates into the host cell DNA, it offers a possibility for long-term expression, and perhaps a "cure." However, this process of random integration is associated with a risk of insertional mutagenesis and tumor formation. Also, the low rates of epithelial cell proliferation in normal human airways have made ret States are focused on the use of adenovirus-mediated gene transfer. Key issues to be addressed for successful gene transfer studies in patients with CF include the following: (1) efficiency; (2) efficacy; and (3) safety.
Efficiency
A previous in vitro study by Johnson and colleagues50 suggested that as few as 6 to 10% of CF airway epithelial cells must be corrected in order to restore normal Cl-transport function to an entire epithelial sheet. Efficient gene transfer using adenovirus vectors has been reported in vivo in cotton rats.49 However, in vivo adenovirus-mediated gene transfer to the airway epithelia of nonhuman primates tends to be of low efficiency and patchy.51 Efficient gene transfer to human airway epithelia in vitro has also been reported. 46 As discussed below, published data from a clinical study in the nasal epithelium of patients with CF may offer some exciting insights into in vivo gene transfer of CFTR in patients with CF.52 Efficacy The current working definition of efficacy is the physiologic demonstration of restoration of normal Cl-transport in CF epithelia following transduction of the wild-type human CFTR. In a previous study, Rosenfeld and colleagues49 reported correction of the CF Cl-permeability defect in a CF pancreatic cell line in vitro and also in vivo CFTR protein expression in cotton rat airway epithelia. More recently, Rich and colleagues46 have reported in vitro correction of the Cl-permeability defect in human CF airway epithelia with a multiplicity of infection (MOI) or number of infectious particles per cell as low as 0.1 to 1 using adenovirus-mediated transduction of CFTR.
To date, the mouse models for CF have not been used extensively in preclinical testing of adenovirus vectors. However, Grubb and colleagues (unpublished data, 1994) have demonstrated partial correction of the Cl-transport defect in the nasal epithelium of their CF mouse model53'54 following in vivo adenovirus-mediated gene transfer to the nasal epithelium. Interestingly, a high MOI was required to partially restore Cl-transport. Moreover, no correction of sodium transport was observed. Recent evidence suggests that the results observed in the nasal studies of Grubb and colleagues may differ from observations in ongoing studies in patients with CF. In a series of three patients, Zabner and colleagues52 have reported correction of Cl-transport function in the nasal epithelium of subjects enrolled in their clinical study of adenovirus-mediated gene transfer for CF at a MOI as low as 1.
Safety
Several safety concerns have been raised with adenovirus vectors, including contamination of virus stocks with recombinant replication competent virus, immune response, ectopic expression, and integration. Contamination of virus stocks can be minimized by screening for replication competent viruses. Perhaps a more worrisome concern is whether the presence of El genes in the affected epithelium of patients with CF, which has been reported to be as high as 10 to 15%,5 will lead to replication of adenovirus vectors in the host. For this reason, current human protocols evaluating safety and efficacy in patients have focused on the use of patients carrying antibodies to adenoviruses serotypes 2 or 5.
Wild-type adenoviruses are known to cause both an acute mixed cellular inflammatory response and a later lymphocyte predominant inflammatory response in rodents. 43 Human safety and efficacy studies are currently underway at five CF centers. These studies are using low doses of adenovirus vectors in small numbers of patients with CF. If no toxicity is seen at the lower doses, the doses will be increased at subsequent stages of these trials. The initial results reported from the trial at the University of Iowa appear to be promising. One severe adverse reaction, that may have been cytokine-mediated, has been reported in one study involving the lower airways.
CONCLUSIONS
Major research efforts have been conducted to develop suitable gene transfer vectors for CF. Although many of these vector systems are still under development and are in need of improvement, initial clinical safety and efficacy trials for gene therapy of CF have begun. Liposome-mediated gene transfer has been the vector system selected for initial clinical studies in the United Kingdom, while clinical safety and efficacy trials in the United States all utilize adenovirus-mediated gene transfer. In this article, we have shown that adenovirus-mediated gene transfer to the airway epithelium can be efficient in vivo, although it may be rather inhomogeneous. Moreover, this method of gene transfer may be efficacious for CF based on evidence from mouse models and ongoing in vivo studies in humans. However, lung inflammation is a major concern with the use of high doses of adenovirus vectors. Moreover, the therapeutic to toxic ratio with repetitive dosing has not been defined. If gene therapy for CF is to become a reality, then continued development of more efficient vectors with improved safety profiles will be required.
